134,000 Shares in Personalis, Inc. (NASDAQ:PSNL) Purchased by 683 Capital Management LLC

683 Capital Management LLC bought a new stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 134,000 shares of the company's stock, valued at approximately $775,000. 683 Capital Management LLC owned 0.19% of Personalis as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Blue Water Life Science Advisors LP lifted its position in Personalis by 13.3% during the fourth quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company's stock worth $6,548,000 after purchasing an additional 132,900 shares during the period. Geode Capital Management LLC boosted its position in shares of Personalis by 20.0% during the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company's stock worth $2,683,000 after acquiring an additional 83,068 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock worth $2,372,000 after acquiring an additional 242,141 shares in the last quarter. Jane Street Group LLC raised its position in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock valued at $2,320,000 after purchasing an additional 237,033 shares in the last quarter. Finally, abrdn plc bought a new stake in Personalis during the fourth quarter worth $1,722,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PSNL. HC Wainwright lifted their price target on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday. Craig Hallum assumed coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 target price on the stock. Lake Street Capital increased their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $7.00 price target on shares of Personalis in a research note on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $8.00.

Personalis Stock Up 16.6 %

Shares of PSNL stock traded up $0.67 during trading hours on Wednesday, hitting $4.67. 974,046 shares of the company's stock traded hands, compared to its average volume of 986,196. The stock has a market cap of $411.96 million, a PE ratio of -2.79 and a beta of 1.83. The stock's 50 day simple moving average is $3.61 and its 200 day simple moving average is $4.45. Personalis, Inc. has a 12 month low of $1.14 and a 12 month high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. As a group, equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.